Prognostic value of RKIP and p-ERK in gastric cancer

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Fujimori, Yoshitaka ^a   Inokuchi, Mikito ^a   Takagi, Yoko ^a   Kato, Keiji ^a   Kojima, Kazuyuki ^a   Sugihara, Kenichi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PEBP1 PROTEIN, HUMAN;

AGED; ARTICLE; CANCER INVASION; CANCER SURGERY; CANCER SURVIVAL; CORRELATION ANALYSIS; ENZYME PHOSPHORYLATION; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; STOMACH ADENOCARCINOMA; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOMACH TUMOR;

EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; KAPLAN-MEIER ESTIMATE; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PHOSPHORYLATION; PROGNOSIS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84859030197     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-30     Document Type: Article

References (40)

1. Global cancer statistics 2002. Parkin DM, Bray F, Ferlay J, Pisani P, CA Cancer J Clin 2005 55 74 108 10.3322/canjclin.55.2.74 15761078
2. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. Kamangar F, Dores GM, Anderson WF, J Clin Oncol 2006 24 2137 2150 10.1200/JCO.2005.05.2308 16682732 (Pubitemid 46655601)
3. Gastric carcinoma. Fuchs CS, Mayer RJ, N Engl J Med 1995 333 32 41 10.1056/NEJM199507063330107 7776992
4. A 10-year experience with Japanese-type radical lymph node dissection for gastric cancer outside of Japan. Jatzko GR, Lisborg PH, Denk H, Klimpfinger M, Stettner HM, Cancer 1995 76 1302 1312 10.1002/1097-0142(19951015)76:8<1302:: AID-CNCR2820760803>3.0.CO;2-8 8620402
5. Cancer surgery: the last 25 years. Bremers AJ, Rutgers EJ, van de Velde CJ, Cancer Treat Rev 1999 25 333 353 10.1053/ctrv.1999.0147 10644500 (Pubitemid 30047573)
6. Prospective cohort study of comprehensive prevention to gastric cancer. Guo HQ, Guan P, Shi HL, Zhang X, Zhou BS, Yuan Y, World J Gastroenterol 2003 9 432 436 12632491 (Pubitemid 36372101)
7. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 69 90 10.3322/caac.20107 21296855
8. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK, ToGA Trial Investigators, Lancet 2010 376 687 697 10.1016/S0140-6736(10)61121-X 20728210
9. Two co-existing mechanisms for nuclear import of MAP kinase: passive diffusion of a monomer and active transport of a dimer. Adachi M, Fukuda M, Nishida E, EMBO J 1999 18 5347 5358 10.1093/emboj/18.19.5347 10508167 (Pubitemid 29465584)
10. Raf kinase inhibitory protein (RKIP): a physiological regulator and future therapeutic target. Zeng L, Imamoto A, Rosner MR, Expert Opin Ther Targets 2008 12 1275 1287 10.1517/14728222.12.10.1275 18781826
11. The role of Raf kinase inhibitor protein (RKIP) in health and disease. Keller ET, Fu Z, Brennan M, Biochem Pharmacol 2004 68 1049 1053 10.1016/j.bcp.2004.04.024 15313400 (Pubitemid 39094269)
12. Modulation of the MAP kinase signaling cascade by Raf kinase inhibitory protein. Trakul N, Rosner MR, Cell Res 2005 15 19 23 10.1038/sj.cr.7290258 15686621 (Pubitemid 41653959)
13. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F, Katsanakis KD, Rose DW, Mischak H, Sedivy JM, Kolch W, Nature 1999 401 173 177 10.1038/43686 10490027 (Pubitemid 29436321)
14. Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Yeung K, Janosch P, McFerran B, Rose DW, Mischak H, Sedivy JM, Kolch W, Mol Cell Biol 2000 20 3079 3085 10.1128/MCB.20.9.3079-3085.2000 10757792 (Pubitemid 30215020)
15. World Medical Association Declaration of Helsinki: Ethical Principales for Medical Research involving Human Subjects. World Medical Association, http://www.wma.net/en/30publications/10policies/b3/17c.pdf
16. Raf kinase inhibitor protein: mechanism of loss of expression and association with genomic instability. Al-Mulla F, Hagan S, Al-Ali W, Jacob SP, Behbehani AI, Bitar MS, Dallol A, Kolch W, J Clin Pathol 2008 61 524 529 10.1136/jcp.2007.046987 18375747 (Pubitemid 351518239)
17. Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma. Feng W, Brown RE, Trung CD, Li W, Wang L, Khoury T, Alrawi S, Yao J, Xia K, Tan D, Ann Clin Lab Sci 2008 38 195 209 18715846
18. Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Hagan S, Al-Mulla F, Mallon E, Oien K, Ferrier R, Gusterson B, Garcia JJ, Kolch W, Clin Cancer Res 2005 11 7392 7397 10.1158/1078-0432.CCR-05-0283 16243812 (Pubitemid 41507699)
19. Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. Al-Mulla F, Hagan S, Behbehani AI, Bitar MS, George SS, Going JJ, Garcia JJ, Scott L, Fyfe N, Murray GI, Kolch W, J Clin Oncol 2006 24 5672 5679 10.1200/JCO.2006.07.5499 17179102 (Pubitemid 46631308)
20. Loss of RKIP expression is associated with poor survival in GISTs. Martinho O, Gouveia A, Silva P, Pimenta A, Reis RM, Lopes JM, Virchows Arch 2009 455 277 284 10.1007/s00428-009-0821-z 19705153
21. Immunohistochemical detection of the Raf kinase inhibitor protein in nonneoplastic gastric tissue and gastric cancer tissue. Wang J, Yang YH, Wang AQ, Yao B, Xie G, Feng G, Zhang Y, Cheng ZS, Hui L, Dai TZ, Du XB, Wang D, Med Oncol 2010 27 219 223 10.1007/s12032-009-9194-z 19291429
22. Inverse association between Raf Kinase Inhibitory Protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome. Chatterjee D, Sabo E, Tavares R, Resnick MB, Clin Cancer Res 2008 14 2994 3001 10.1158/1078-0432. CCR-07-4496 18483365
23. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA, Biochim Biophys Acta 2007 1773 1263 1284 10.1016/j.bbamcr.2006.10.001 17126425 (Pubitemid 47125967)
24. Increased expression of mitogen-activated protein kinase and its upstream regulating signal in human gastric cancer. Liang B, Wang S, Zhu XG, Yu YX, Cui ZR, Yu YZ, World J Gastroenterol 2005 11 623 628 15655810 (Pubitemid 40220747)
25. Stimulus-induced uncoupling of extracellular signal-regulated kinase phosphorylation from nuclear localization is dependent on docking domain interactions. Caunt CJ, McArdle CA, J Cell Sci 2010 123 4310 4320 10.1242/jcs.076349 21123621
26. TRAPPC4-ERK2 interaction activates ERK1/2, modulates its nuclear localization and regulates proliferation and apoptosis of colorectal cancer cells. Zhao SL, Hong J, Xie ZQ, Tang JT, Su WY, Du W, Chen YX, Lu R, Sun DF, Fang JY, PLoS One 2011 6 23262 10.1371/journal.pone.0023262 21826244
27. Decreased MAP kinase activity in human gastric adenocarcinoma. Atten MJ, Attar BM, Holian O, Biochem Biophys Res Commun 1995 212 1001 1006 10.1006/bbrc.1995.2069 7626085
28. Tumor-specific activation of mitogen-activated protein kinase in human colorectal and gastric carcinoma tissues. Kuno Y, Kondo K, Iwata H, Senga T, Akiyama S, Ito K, Takagi H, Hamaguchi M, Jpn J Cancer Res Japan 1998 89 903 909 10.1111/j.1349-7006.1998.tb00647.x (Pubitemid 28486815)
29. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Kolch W, Biochem J 2000 351 289 305 10.1042/0264-6021:3510289 11023813
30. Prevalence of ras gene mutations in human colorectal cancers. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, Vogelstein B, Nature 1987 327 293 297 10.1038/327293a0 3587348 (Pubitemid 17075079)
31. Ras oncogenes: split personalities. Karnoub AE, Weinberg RA, Nat Rev Mol Cell Biol 2008 9 517 531 10.1038/nrm2438 18568040 (Pubitemid 351881844)
32. Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. Kim IJ, Park JH, Kang HC, Shin Y, Park HW, Park HR, Ku JL, Lim SB, Park JG, Hum Genet 2003 114 118 120 10.1007/s00439-003-1027-0 14513361 (Pubitemid 38165543)
33. MAP kinase signalling pathways in cancer. Dhillon AS, Hagan S, Rath O, Kolch W, Oncogene 2007 26 3279 3290 10.1038/sj.onc.1210421 17496922 (Pubitemid 46763021)
34. High expression of HER3 is associated with a decreased survival in gastric cancer. Hayashi M, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, Kawano T, Sugihara K, Clin Cancer Res 2008 14 7843 7849 10.1158/1078-0432.CCR- 08-1064 19047113
35. Relation between outcomes and localisation of p-mTOR expression in gastric cancer. Murayama T, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, Kawano T, Sugihara K, Br J Cancer 2009 100 782 788 10.1038/sj.bjc.6604915 19223902
36. Targeting the mitogen-activated protein kinase cascade to treat cancer. Sebolt-Leopold JS, Herrera R, Nat Rev Cancer 2004 4 937 947 10.1038/nrc1503 15573115 (Pubitemid 39626217)
37. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Friday BB, Adjei AA, Clin Cancer Res 2008 14 342 346 10.1158/1078-0432.CCR-07-4790 18223206 (Pubitemid 351226098)
38. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Pratilas CA, Solit DB, Clin Cancer Res 2010 16 3329 3334 10.1158/1078-0432.CCR-09-3064 20472680
39. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Roberts PJ, Der CJ, Oncogene 2007 26 3291 3310 10.1038/sj.onc.1210422 17496923 (Pubitemid 46763022)
40. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, Tan SH, Wu J, Lee MH, Ooi CH, Rha SY, Wong WK, Boussioutas A, Yeoh KG, So J, Yong WP, Tsuburaya A, Grabsch H, Toh HC, Rozen S, Cheong JH, Noh SH, Wan WK, Ajani JA, Lee JS, Tellez MS, Tan P, Gastroenterology 2011 141 476 485 10.1053/j.gastro.2011.04.042 21684283